Wed, 01st Jul 2020 13:10
ValiRx PLC - London-based clinical stage biotechnology company - Pretax loss narrowed in 2019 to GBP2.7 million from GBP4.8 million. Research and development costs down 42% to GBP984,457, and administrative expenses trimmed 14% to GBP1.9 million. Like in 2018, ValiRx generated no revenue.
Current stock price: 7.29 pence
Year-to-date change: down 51%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
(Alliance News) - ValiRx PLC on Thursday said that it has signed an evaluation deal with Imperial College London to look at research on novel therapeu...
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...
(Alliance News) - ValiRx PLC on Tuesday said a requisition notice, which it received earlier in February, has been confirmed as invalid following lega...
(Sharecast News) - ValiRx announced the signing of a significant agreement with the University of Dundee and its Drug Discovery Unit (DDU) on Monday.
ValiRx PLC - Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics - Signs agreement with Dundee University's drug ...
ValiRx (VAL)